A vast shadow will sweep over Saturn's cloud tops early on July 18: Here's how to see it
Early risers will get a rare opportunity to see something extraordinary in the early hours of July 18 — the dark shadow of Saturn's largest moon, Titan, sweeping across the planet's cloud tops.
Once every 15 years, Saturn's tilted orbit brings its iconic rings — and Titan's orbital path — into an edge-on alignment with Earth. This event, known as a ring-plane crossing, heralds the onset of a season of dramatic 'shadow transits', as Titan's vast umbral silhouette periodically sweeps across the gas giant's surface.
"Sighting a shadow transit of Titan for an amateur astronomer is somewhat the equivalent of a fisherman hooking and reeling in a particularly large or elusive fish," Hayden Planetarium instructor and lecturer Joe Rao told Space.com in an email. "It is so unusual a sight that doesn't happen very often, which is why even veteran skywatchers are excited at the possibility of making such a sighting."
When is Titan's shadow transit?
Titan's next shadow transit will get underway at 3 a.m. EDT (0700 GMT) on July 18, at which time the moon's dark outline will be visible slowly progressing across Saturn's cloudy disk, according to Sky and Telescope.
Look for Saturn in the southeastern sky, just below the stars of the constellation Pisces shining like a bright star to the naked eye, with the moon in the east.
Observers in the U.S. will have a good view of the first two hours of the shadow transit, but by the time Titan's shadow leaves Saturn's disk at 8:05 a.m. EDT (12:05 GMT), the brightening dawn will overpower the view.
How powerful does a telescope need to be to spot Titan's shadow?
At the time of the shadow transit, Titan and Saturn will be separated by approximately 846 million miles (1.36 billion kilometers) from Earth — far beyond the capabilities of the naked eye or binoculars, but well within reach of many amateur telescopes.
We asked Rao for guidance on the kind of scope needed to view Titan's shadow transit. "An 8-inch telescope at 200-power or a 10-inch telescope at 250-power should provide a good view of Titan's shadow, especially on a night of good seeing," Rao explained.
To calculate the magnifcation of your telescope, you need only divide its focal length by the focal length of your chosen eyepiece. For example, a 1000 mm telescope with a 10 mm eyepiece yields 100-power magnification.
Rao also emphasised that stable atmospheric conditions are crucial to obtaining a clear view. This becomes more important when using higher power with a smaller aperture scope. It's best to use one-half magnification/power when viewing distant objects to avoid them appearing to "boil", or "scintilate" when viewed through the eyepiece.
"At least 200-power is necessary for getting a reasonably good view of the dark 'shadow dot' projected on Saturn's disk," continued Rao. "The general rule of thumb is to utilize 50-power for every inch of aperture of the telescope objective, or mirror. So, for a 4-inch telescope, the maximum magnification to be used is 200-power, which is considered the limit for a telescope of that size."
When are the next Titan shadow transits?
After the July 18 event, five more Titan shadow transits will be visible from Earth. Each occurs roughly16 days after the last — a result of Titan's 16-day orbital period — and starting progressively earlier in the night for viewers in the U.S.
Date
Start
End
Aug 3
2:25 a.m.
7:04 a.m.
Aug 19
1:52 a.m.
6:00 a.m.
Sept 4
1:25 a.m.
4:50 a.m.
Sept 20
1:09 a.m.
3:34 a.m.
Oct 6
1:32 a.m.
The next transit after this week will begin at 2:25 a.m. (0625 GMT) on August 3, while the last chance to catch the moon's shadow fall on Saturn will take place on October 6.
After the October event, stargazers will have to wait another 15 years before the next ring crossing brings Titan — and its shadow — into alignment once more!
Titan's shadow through the eyes of the Cassini spacecraft
Without question, the most spectacular views of a Titan shadow transit came courtesy of NASA's Cassini spacecraft, which witnessed the moon's dark outline fall over Saturn's cloud surface in November 2009, while it travelled a mere 1.3 million miles (2.1 million km) from the colossal gas giant. Cassini has long since found its resting place beneath the cloud surface of Saturn, but amateur astronomers will have an opportunity to follow in Cassini's steps later this week and witness the next Titan shadow transit for themselves when it takes place on July 18.
"Though we, living in the 21st century, have grown accustomed to seeing the Saturnian system through the eyes of Cassini, there still remains the thrill of witnessing, with one's own eyes, a major celestial event in the life of another planet a billion miles away," Carolyn Porco, planetary scientists and imaging team leader for NASA's Cassini mission told Space.com in an email.
Editor's Note: If you would like to share your images of the Titan shadow transit with Space.com's readers, then please send your photo(s), comments, and your name and location to spacephotos@space.com.
Solve the daily Crossword
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hamilton Spectator
5 minutes ago
- Hamilton Spectator
Radar satellite launched by India and NASA will track miniscule changes to Earth's land and ice
CAPE CANAVERAL, Fla. (AP) — NASA and India paired up to launch an Earth-mapping satellite on Wednesday capable of tracking even the slightest shifts in land and ice. The $1.3 billion mission will help forecasters and first responders stay one step ahead of floods, landslides, volcanic eruptions and other disasters , according to scientists. Rocketing to orbit from India , the satellite will survey virtually all of Earth's terrain multiple times. Its two radars — one from the U.S. and the other from India — will operate day and night, peering through clouds, rain and foliage to collect troves of data in extraordinary detail. Microwave signals beamed down to Earth from the dual radars will bounce back up to the satellite's super-sized antenna reflector perched at the end of a boom like a beach umbrella. Scientists will compare the incoming and outgoing signals as the spacecraft passes over the same locations twice every 12 days, teasing out changes as small as a fraction of an inch (1 centimeter). It's 'a first-of-its-kind, jewel radar satellite that will change the way we study our home planet and better predict a natural disaster before it strikes,' NASA's science mission chief Nicky Fox said ahead of liftoff. Fox led a small NASA delegation to India for the launch. It will take a full week to extend the satellite's 30-foot (9-meter) boom and open the 39-foot-in-diameter (12-meter) drum-shaped reflector made of gold-plated wire mesh. Science operations should begin by the end of October. Among the satellite's most pressing measurements: melting glaciers and polar ice sheets; shifting groundwater supplies; motion and stress of land surfaces prompting landslides and earthquakes; and forest and wetland disruptions boosting carbon dioxide and methane emissions. NASA is contributing $1.2 billion to the three-year mission; it supplied the low-frequency radar and reflector. The Indian Space Research Organization's $91 million share includes the higher-frequency radar and main satellite structure, as well as the launch from a barrier island in the Bay of Bengal. It's the biggest space collaboration between the two countries. The satellite called NISAR — short for NASA-ISRO Synthetic Aperture Radar — will operate from a near-polar-circling orbit 464 miles (747 kilometers) high. It will join dozens of Earth observation missions already in operation by the U.S. and India. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Forbes
6 minutes ago
- Forbes
How AI Could Spark A Jobs Revolution In Africa: Sam Alemeyahu's Vision
While the world debates whether AI will destroy jobs, Sam Alemayehu wants to talk about the ones that never existed in the first place. The Ethiopian-American investor and entrepreneur has built his career around challenging assumptions — whether by turning landfills into power plants or by turning scarcity into opportunity. Known as 'Garbage Sam' for his pioneering work on Africa's first waste-to-energy facility, Alemayehu is now applying that same systems lens to a broader question: How do we design abundance? In a recent essay for Rest of World, Alemayehu introduced the provocative concept of 'latent jobs' — roles that should exist but don't, because legacy systems made them economically impossible. He argues that AI, far from being a threat, could finally unleash a new tier of professionals across Africa — if we let it. We spoke about waste, imagination, and what it means to build systems designed for as 'Garbage Sam' for his pioneering work on Africa's first waste-to-energy facility, Sam ... More Alemayehu is now applying that same systems lens to a broader question: How do we design abundance? Q&A Sylvana Q. Sinha: In your recent piece for Rest of World, you argue that AI could help create new jobs across Africa — roles that never existed before. What kind of jobs are you talking about, and why do they matter? Sam Alemayehu: I call them 'Latent Jobs.' They are essential roles that have never emerged — not because there's no demand, but because the cost of creating and sustaining them under our traditional systems is too high. We don't just have a shortage of professionals in Africa; we have a shortage of affordable access to expertise. Take healthcare. Ethiopia has fewer than 10,000 physicians for over 120 million people. But there are more Ethiopian-trained doctors in places like D.C. and Chicago than in the country itself. It's not a talent shortage — it's a system failure. AI changes that. It breaks the cost structure. A radiologist's expertise can be delivered, in part, by an AI diagnostic tool for a fraction of the price. Suddenly, that 'latent job' — a role that previously didn't exist because it was economically unviable — becomes real. And not just one job, but Q. Sinha: Fascinating! What's another example of a latent job? Sam Alemayehu: It's a pattern that's emerging everywhere, creating an entirely new class of tech-enabled professionals. Think of a community health worker in Lusaka using an AI that analyzes a baby's cry to detect birth asphyxia instantly. Picture an agronomist in Ethiopia using a drone to guide a hundred farms at once, stopping crop disease in its tracks. Imagine a paralegal in Lagos delivering affordable, AI-vetted contracts to small businesses right through WhatsApp. Or a surveyor in rural Peru using AI to map a ravine and design a safe footbridge in an afternoon, a study that once took months and was prohibitively expensive. Each of these was a 'latent job.: The need was immense, but the old model was too slow and too costly. Technology is the catalyst that finally makes these essential roles real, affordable, and Q. Sinha: I love this framing. It reminds me of Nobel laureate Amartya Sen's insight from his work on famines, especially in Poverty and Famines (1981): People don't starve because there's no food — they starve because they can't access it. It's not about scarcity, but about systems. You call this systemic failure the 'Scarcity Tax.' What do you mean by that? Sam Alemayehu: The Scarcity Tax is the invisible, uncounted cost of a system that fails to make expertise accessible. It's a price paid daily by citizens, farmers, and entrepreneurs, particularly in the Global South. It's the crop lost because a farmer couldn't get an agronomist's advice. It's the failed business because a founder couldn't afford a lawyer. It's the child who dies from a treatable illness because a doctor wasn't nearby. What's tragic is that this tax isn't necessary. It's not about lacking intelligence or motivation. It's about a broken system for distributing knowledge. AI gives us a chance to redesign that system — and finally make expertise Q. Sinha: You've been called 'Garbage Sam' — a nickname that started at a landfill in Addis Ababa. How did waste become your life's lens? Sam Alemayehu: I got that name when I led the team that built Africa's first major waste-to-energy facility. I spent a lot of time at the landfill — and what I saw shocked me. It wasn't trash; it was a graveyard of value. Plastics, metals, nutrients, energy — all of it buried. Nature doesn't waste anything. Everything gets reused. So when we treat resources as disposable, that's not a garbage problem — it's a design problem. The same thinking that leads us to bury useful materials is what leads us to waste land, water, and human potential. That's the war I've committed to fighting: the war on waste in all its Q. Sinha: You've also written about the waste embedded in how we make things — from food to steel to cement. What gives you hope that we can build differently? Sam Alemayehu: Once you put on the 'anti-waste' lens, you see how inefficient our physical economy is. Food production alone is the leading driver of deforestation, land degradation, and wildlife extinction. The FAO projects that by 2050, just to meet protein demand, we'd need to deforest an area twice the size of India. That's not just unsustainable — it's apocalyptic. But we now have tools to break that pattern. Synthetic biology can grow proteins with a fraction of the land and water. New chemical processes can produce cement or textiles with near-zero emissions. Innovation becomes the engine for deconstructing waste — not just at the end of the supply chain, but at the Q. Sinha: What does your vision of an AI-powered, waste-free Africa look like in 20 years? Sam Alemayehu: It's a world where waste — of talent, resources, and opportunity — is no longer the default. A world where a mother in Kampala can access high-quality care, a farmer in Ethiopia can access agronomic advice, and a young entrepreneur in Lagos can get legal support — all augmented by AI. It's also a world where we rewild vast areas of land, because we've finally decoupled economic growth from physical extraction. Where technology doesn't replace nature, but learns from it — circular, adaptive, and efficient. That's the future I'm building toward. A world designed for abundance — not for the privileged few, but for Q. Sinha: What would it take to actually realize this vision — of millions of AI-augmented jobs and a waste-free economy? Who needs to act, & how? Sam Alemayehu: This future isn't inevitable; it has to be built. It requires a coordinated effort from three groups: First, entrepreneurs and innovators. They are the ones on the ground, building the tools, training the new workforce, and fine-tuning these models for local languages, cultures, and realities. This is a bottom-up revolution. Second, largest corporate champions. Companies like MTN, Safaricom, and big regional banks in Africa have a historic opportunity. They need to become the first customers and partners for this new wave of innovation. By integrating these AI-augmented services into their vast distribution networks, they can create the market and accelerate adoption overnight. Finally, policymakers. We need a new regulatory imagination. The old rules for credentialing and liability were designed for a world of scarcity. We must build modern frameworks that judge innovation based on its effectiveness, not just on traditional credentials. We need faster, clearer pathways to professional legitimacy for this new, AI-augmented workforce. It's symbiotic — entrepreneurs build, corporations scale, and policymakers clear the path. If those three groups act in concert, this vision becomes a reality much faster than anyone can Q. Sinha: Do you see opportunities for investors in this space? What kinds of investors can be part of this future? Sam Alemayehu: The opportunity is massive — it fights waste on two critical, parallel fronts: On one side, you have the chance to finance the redesign of our industrial economy — food and materials that are cleaner, cheaper, and superior to legacy models. On the other side, you have the Latent Jobs revolution — unlocking the 'old world's' advantages in high value skills in healthcare, law, engineering through AI. That's how we can build a workforce for a world of abundance. This isn't just theory — it's what we are building. Through Cambridge Industries Ventures (CI Ventures), we are backing businesses that are building the "manufacturing of the future". Through our Latent Jobs Fund, we are building and scaling the platforms that unleash that AI-augmented workforce. It will take a whole ecosystem of capital to build this future — and we are committed to being a catalyst in that Q. Sinha: Your work often focuses on Africa — but isn't the potential here much broader? After all, emerging markets account for 80% of the global population, and more than 70% of that is in Asia. Why limit this opportunity to Africa? Sam Alemayehu: You're right, this is a global opportunity. The 'Latent Jobs' thesis applies anywhere human potential is stifled by outdated systems. My focus often begins in Africa because it's personal, but more importantly, I see it as the ultimate proving ground. With the youngest and fastest-growing population, the need is most acute, which forces the most resilient and scalable solutions. However, I don't see this as a one-way street where innovations flow from Africa outward. The transformation will be shared, with innovation happening simultaneously across the Global South. The key will be to build partnerships and strong collaborations between these emerging innovation hubs in Latin America, Southeast Asia, and Africa to accelerate this new future Q. Sinha: Thank you. In a world obsessed with what AI might take away, Sam Alemayehu invites us to see what it can finally make possible. The future of work, it turns out, may begin where the world never thought to look.
Associated Press
6 minutes ago
- Associated Press
Measles Cases Increasing Worldwide, Need the New NV-387 Broad-Spectrum Antiviral to Combat, Says NanoViricides
SHELTON, CT / ACCESS Newswire / July 30, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the 'Company'), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, announced that its drug candidate NV-387 is the weapon necessary for combatting growing cases of measles worldwide, especially in the industrialized world including, USA, Canada, UK, and European Union. NV-387 is possibly the only drug candidate that has been shown to be effective and safe in animal model studies of Measles virus in humanized h-CD150+ knock-in mice, as reported previously by NanoViricides. NV-387 has completed a Phase I clinical trial with no reported adverse events, indicating excellent safety and tolerability in humans. The development of NV-387 as a treatment for Measles can be accelerated under the US FDA programs. Measles is considered a rare orphan disease in the USA. As such, NV-387 for the treatment of Measles would qualify for an Orphan Drug Designation. Orphan drug designation qualifies sponsors for incentives including tax credits for qualified clinical trials, exemption from user fees, and potential seven years of market exclusivity after approval[1]. The Company also plans to explore a 'Fast Track' designation for the NV-387 Measles indication. If granted, a drug approval can occur on the basis of a successful Phase II clinical trial without requiring a Phase III clinical trial, which significantly reduces the timeline to approval. Measles has become an important disease of concern globally in the recent years for several reasons. Most importantly, Measles disease can wipe out the previously learned immunity of the patient against many infections, including from prior infections, and non-live virus vaccines, making the population vulnerable to viruses that were encountered previously. This is because Measles virus attacks the CD150-bearing immune cells that are responsible for memorizing the prior infections and mounting defenses against them later. Measles is possibly the most communicable diseases, spreading through aerosol, that is known to humans. In patients, it produces severe morbidity with skin rash, pain, fatigue, and other syndromes. Rarely it can cause a brain disease. Measles mostly affects children. There were a total of 1,319 confirmed measles cases reported in the USA as of July 22, breaking the most recent record of 1,274 cases in 2019. Hospitalization rates for measles in the USA are about 13%, and fatalities are rare, although in 2025 there were three deaths to date. Canada is having a much worse Measles season than the USA, with more than 3,800 cases[2] to date in 2025. A Measles holiday warning has been issued in the UK this year[3]. England itself had more than 3,000 cases of Measles in 2024. In the European Region, 127,350 measles cases were reported for 2024, double the number of cases reported for 2023 and the highest number since 1997, according to an analysis by WHO and the United Nations Children's Fund (UNICEF)[4] . Worldwide, Measles cases continue to occur every year. Globally, there have been about 108,000 confirmed measles cases in 2025 to date, while in 2024 there were about 360,000 confirmed cases, according to the WHO[5]. A sustained measles vaccination rate of at least 95% is estimated to be required to maintain community immunity ('herd immunity'). Such a high rate is becoming increasingly difficult to achieve even in developed countries where access to vaccination is not an issue. While growing vaccine hesitancy is considered an important reason for the fall in Measles vaccination rates, two other factors are of importance as well: (i) The overall population in the industrialized world, as well as in developing world, has increased frequency of immune dysfunction, obesity, and diabetes. The people with immune dysfunction or immune compromise are less likely to benefit from almost any standard vaccination as compared to healthy people and are likely to result in breakthrough infections. (ii) Additionally, the current vaccine for Measles is a live attenuated vaccine of the 1968 era, and the virus has evolved well past that, although so far the Measles virus strains continue to be susceptible to antibodies produced from the standard vaccine; this can change with continuing circulation of the virus in vaccinated persons and can result in a virus that can substantially defeat the vaccine[6]. Further, vaccine hesitancy itself is not irrational because the standard Measles vaccine is a live attenuated vaccine to be given to infants at early age; it is a virus infection that continues to remain in the subject, which is why it provides lifelong immunity. Measles infection itself also provides lifelong immunity that includes the current strains of the virus. Thus, the Company projects continuing Measles cases worldwide, that require a drug to control the disease in the patient and its spread to others. We believe NV-387 fills this important medical need. There is no approved drug for treatment of Measles at present. ABOUT NANOVIRICIDES NanoViricides, Inc. (the 'Company') ( ) is a publicly traded (NYSE-American, stock symbol NNVC) clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide™ class of drug candidates and the nanoviricide™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments. The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company's business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005. Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials. The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides' platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company's pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product. This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading 'Risk Factors' and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products. The phrases 'safety', 'effectiveness' and equivalent phrases as used in this press release refer to research findings including clinical trials as the customary research usage and do not indicate evaluation of safety or effectiveness by the US FDA. FDA refers to US Food and Drug Administration. IND application refers to 'Investigational New Drug' application. cGMP refers to current Good Manufacturing Practices. CMC refers to 'Chemistry, Manufacture, and Controls'. CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency's (EMA) committee responsible for human medicines. API stands for 'Active Pharmaceutical Ingredient'. WHO is the World Health Organization. R&D refers to Research and Development. Contact: NanoViricides, Inc. [email protected] Public Relations Contact: [email protected] press release
